A personalized mRNA vaccine called intismeran, developed by Moderna, has shown significant results in reducing the risk of melanoma recurrence when combined with the immunotherapy drug pembrolizumab, sold under the brand name Keytruda. The findings come from the phase 2b KEYNOTE-942 trial and were presented at the 2026 annual meeting of the American Society of Clinical Oncology in Chicago and published in the Journal of Clinical Oncology.

The trial enrolled 157 patients with Stage III or Stage IV melanoma that had been surgically removed. Patients were randomly assigned in a two-to-one ratio, with 107 receiving the combination of intismeran plus pembrolizumab and 50 receiving pembrolizumab alone. At the five-year mark, the combination therapy reduced the risk of recurrence or death by 49 percent compared to pembrolizumab by itself. The hazard ratio was 0.510, with a 95 percent confidence interval of 0.294 to 0.887, and the result was statistically significant.

After five years, 68.8 percent of patients in the combination group remained cancer-free, compared to 49.1 percent in the monotherapy group. Overall survival at five years was 92.2 percent in the combination group versus 71.3 percent in the monotherapy group. The combination also reduced the risk of distant metastasis or cancer spreading to other parts of the body by 59 to 62 percent. The median recurrence-free survival could not be calculated in the combination group because so many patients remained disease-free, while in the monotherapy group it was 42.51 months.

The benefit of the combination was seen across all subgroups analyzed, regardless of PD-L1 status, tumor mutational burden, or circulating tumor DNA levels. Overall survival data showed an encouraging trend in favor of the combination, with a hazard ratio of 0.425, but the wide confidence interval means the result is not yet conclusive.

The vaccine uses genetic material from each patient's own tumor to create a personalized treatment. Doctors sequence a patient's tumor to identify up to 34 unique molecular markers called neoantigens and encode them into the vaccine. When injected, the vaccine trains the body's T cells to recognize and target those specific markers. Patients in the combination arm received up to nine doses of the vaccine administered intramuscularly every three weeks, along with up to 18 cycles of intravenous pembrolizumab at 200 milligrams every three weeks for up to one year.

Pembrolizumab works by blocking checkpoint molecules that cancer cells use to hide from the immune system, while the vaccine directs T cells toward the specific markers found on each patient's tumor.

On the safety side, all patients in the combination arm experienced at least one adverse event, compared to 92 percent in the monotherapy arm. Grade 3 or higher adverse events occurred in 34.6 percent of combination patients and 36.0 percent of monotherapy patients. Serious adverse events were reported in 14.4 percent of the combination group and 10 percent of the monotherapy group. The most common side effects in the combination arm were fatigue at 60.6 percent, injection site pain at 56.7 percent, chills at 49.0 percent, fever at 48.1 percent, and headache at 31.7 percent. Seven patients in each group died during the follow-up period, most from cancer.

Marjorie Green, senior vice president and head of oncology global clinical development at Merck Research Laboratories, stated that demonstrating the longer-term potential of the combination to reduce recurrence risk in melanoma represents a meaningful milestone.

Melanoma is the deadliest form of skin cancer. In the United States, an estimated 112,000 new cases are expected in 2026, with about 65,400 cases in men and 46,600 in women. Approximately 8,500 deaths from melanoma occur in the United States each year. In about half of patients, the disease returns within the first five years of treatment. Deaths from melanoma have declined sharply over the past decade due to advances in treatment.

The study was led by researchers at NYU Langone Health and its Perlmutter Cancer Center. Patients were enrolled at cancer centers in Australia and the United States between 2019 and 2021. The trial was funded by Moderna Inc. and Merck & Co. and is registered under the identifier NCT03897881.

A larger phase 3 trial involving nearly 1,000 patients across the United States, Australia, and Europe has completed treatment, and researchers are compiling the results. Once the results are analyzed, Moderna and Merck plan to seek FDA approval. Researchers are also studying whether mRNA vaccines could be used to prevent recurrence of other cancers, including lung cancer. Additional data on secondary endpoints and further follow-up analyses are expected to be shared at an upcoming medical conference.

Original Sources: 1, 2, 3, 4, 5, 6, 7, 8 (moderna) (australia) (europe) (melanoma) (immunotherapy)

This article provides limited actionable information for a normal reader. There are no clear steps, instructions, or tools that a person can use in their daily life. The article describes a clinical trial for a personalized mRNA vaccine developed by Moderna, reports on melanoma recurrence rates, and discusses the potential for future cancer treatments, but it does not explain how a typical person might respond to any of this information. A reader who wants to understand whether this vaccine is available to them, how to access it, or what to ask their doctor would need to consult a medical professional directly. The article does not provide guidance on how to evaluate news about experimental treatments, how to assess the reliability of early trial results, or how to think about the difference between a phase 2 and phase 3 trial. For most readers, this article offers no immediate action to take beyond being aware that a promising new treatment is being studied.

The educational depth is moderate but uneven. The article explains that the vaccine uses mRNA technology to train T-cells to recognize neoantigens on cancer cells, which gives a basic sense of how the treatment works. It provides specific numbers, such as the 70 percent cancer-free rate in the vaccine group compared to 49 percent in the standard treatment group, and the claim that the vaccine cut metastasis risk by nearly 60 percent. These numbers give a sense of scale, but the article does not explain how they were calculated, what the confidence intervals are, or how they compare to other immunotherapy results. The article mentions that the vaccine is personalized using genetic material from each patient's tumor, but it does not explain how this process works, how long it takes, or what makes one patient's neoantigens different from another's. The claim that the vaccine appears to have low toxicity is presented without any detailed comparison to the side effects of standard immunotherapy. A reader comes away with a general picture but not a deep understanding of the science or the trial design.

Personal relevance is limited for most readers. The article is directly relevant to people who have been diagnosed with Stage 3 or Stage 4 melanoma, or who have a family history of melanoma and want to stay informed about emerging treatments. For those readers, knowing that a personalized vaccine is in trials and showing promise could inform conversations with their oncologist about clinical trial eligibility or future treatment options. However, the article does not explain who might qualify for such a trial, how to find one, or what questions to ask. For readers without a personal connection to melanoma, the information is a general awareness piece about a medical advance that does not directly affect daily health, finances, or personal decisions. The mention of mRNA technology might interest people who followed the development of Covid vaccines, but the article does not connect this to actionable information about vaccine safety, availability, or cost. For the general public, the article is informative but not personally impactful in a practical sense.

The public service function is narrow. The article informs readers about a promising clinical trial result and the potential for a new type of cancer treatment. It serves as a general awareness piece about a significant medical development. However, it does not provide specific safety guidance for melanoma patients, warnings about the risks of experimental treatments, or steps a person could take to reduce their risk of melanoma recurrence. It does not offer context for how readers might think about the reliability of early trial results, or how to assess whether a reported benefit is likely to hold up in larger studies. The article reports on findings without empowering the reader to respond constructively or to evaluate the information critically.

The practical advice in the article is nonexistent. There are no steps, tips, or recommendations for any audience. The article does not tell a reader how to evaluate whether the reported benefits of the vaccine are likely to be replicated in the phase 3 trial, how to compare this treatment to existing options, or how to think about the tradeoffs between experimental and standard therapies. It does not offer guidance on how to form an informed opinion about personalized medicine, mRNA technology, or the ethics of tailoring treatments to individual patients. The article is purely informational and does not translate its content into any form of practical guidance.

The long term impact of reading this article is modest. A reader may come away with a sense that personalized cancer vaccines are a promising area of research and that mRNA technology has applications beyond infectious disease. However, the article does not teach a framework for understanding how clinical trials work, how to interpret survival statistics, or how to evaluate the credibility of medical claims made in press releases or conference presentations. It does not help a reader plan ahead, make stronger decisions, or develop habits that would serve them well in interpreting similar news in the future. The information is timely but not enduring in its usefulness.

The emotional and psychological impact is mixed. The article describes a serious disease and a hopeful new treatment, which could provide comfort to patients and families affected by melanoma. However, the strong positive language, including phrases like "significant promise" and "major shift in cancer treatment," could also create unrealistic expectations, especially for patients who may not have access to the treatment for years, if at all. The article does not offer any constructive way to think about the uncertainty that comes with early trial results, or how to manage hope and caution at the same time. The article does not harm the reader, but it also does not provide emotional or intellectual support for processing the information.

The article does not rely on clickbait or ad driven language. The tone is straightforward and grounded in reported findings. The claim that the vaccine could represent a "major shift in cancer treatment" adds some drama, but the article does not sensationalize the data or use exaggerated language to maintain attention. The topic of a cancer vaccine breakthrough has inherent interest, and the article does not overplay this angle.

The article misses several important chances to teach and guide. It does not explain how a person might evaluate whether the reported benefits are likely to hold up in the larger phase 3 trial, what the broader implications of personalized medicine might be for healthcare costs and access, or how to think about the difference between a treatment that works in a trial and one that works in the real world. It does not provide context for how readers might assess the credibility of claims made by a company with a financial stake in the results, or how to weigh the benefits of an experimental treatment against its unknown risks. It does not suggest resources for readers who want to learn more about clinical trials, melanoma treatment options, or how to interpret medical statistics.

Even without those details, a reader can take sensible steps when thinking about experimental cancer treatments and their implications. First, when you hear about a promising new treatment in early trials, remember that many treatments that look good in small studies do not hold up in larger ones, so it is wise to wait for phase 3 results before drawing conclusions. Second, if you or someone you know has melanoma, the best step is to talk to an oncologist about current standard treatments and whether any clinical trials are available in your area, because a doctor can give personalized advice based on your specific situation. Third, when reading about survival statistics, remember that percentages can sound impressive without telling you the full story, so it is important to ask what the actual numbers mean for individual patients. Fourth, when a company develops a treatment and also promotes the results, consider that the company has a financial interest in the outcome, and look for independent sources that confirm the findings. Fifth, if you want to stay informed about medical advances, focus on understanding the basics of how clinical trials work, because this knowledge will help you evaluate new claims more critically over time. These general practices help you stay informed, think carefully, and make better decisions even when the original reporting offers little guidance on how to do so.

The text says the vaccine has shown "significant promise" and calls the results a "major shift in cancer treatment." These words make the vaccine sound like a big win before all the proof is in. The bias helps Moderna and the researchers look good. It hides that the phase 3 trial results are not finished yet.

The text says "nearly 70 percent of patients who received the vaccine were cancer-free, compared to 49 percent of those who received standard treatment alone." The word "nearly" is soft and hides the exact number. This makes the reader think the vaccine works very well. The bias helps the side that wants people to trust the vaccine.

The text says adding the vaccine "cut the risk of cancer metastasizing by nearly 60 percent." The word "nearly" hides the real number again. This pushes the reader to think the vaccine is a big success. It hides how much uncertainty is still in the data.

The text says "each vaccine is designed using genetic material from the patient's tumor." This makes the treatment sound special and high-tech. The bias helps Moderna look like a leader in new science. It hides how expensive or hard this treatment might be for regular people.

The text says the vaccine "trains immune cells known as T-cells to recognize and attack these targets." The word "trains" makes the body sound like a student learning something new. This makes the science feel simple and safe. The bias helps the reader trust the treatment without asking hard questions.

The text says "side effects reported were similar to those from mRNA Covid vaccines, including flu-like symptoms such as chills and headaches that lasted only a couple of days." The phrase "only a couple of days" makes the side effects sound small and not serious. The bias helps the vaccine look safe. It hides any side effects that might have lasted longer or been worse.

The text says "patients whose cancers did not return also showed the most robust immune response after vaccination." This leads the reader to believe the vaccine caused the good results. It hides other reasons why some patients might have stayed cancer-free. The bias makes the vaccine seem like the only reason people got better.

The text says "a larger phase 3 trial involving 1,000 patients across the United States, Australia, and Europe has completed treatment, and researchers are now compiling the results." The phrase "now compiling the results" hides whether the results are good or bad. The bias keeps the reader hopeful even though the big test is not done yet.

The text says "if that trial yields similar findings, experts say it could represent a major shift in cancer treatment." The word "if" hides whether this will really happen. The phrase "experts say" does not name which experts. The bias pushes the reader to believe the vaccine will change everything. It hides any experts who might disagree.

The text says "potentially opening the door to personalized mRNA vaccines for many other types of cancer beyond melanoma." The word "potentially" is soft and hides whether this is a real plan or just a hope. The bias helps Moderna and other companies look like they will cure more cancers. It hides how long this might take or if it will work at all.

The text says "melanoma is the deadliest form of skin cancer." This strong word makes the reader feel scared and grateful for the vaccine. The bias helps the story feel urgent. It hides other skin cancers that might also be dangerous.

The text says "in about half of patients, the disease returns within the first five years of treatment." The phrase "about half" is soft and hides the exact number. This makes the problem sound very big. The bias helps the reader see why the vaccine is needed. It hides any treatments that might already work well.

The text says "surgery remains the first line of treatment, but undetectable cancer cells often remain in the body afterward." The word "often" hides how common this really is. The bias makes surgery sound like it is not enough. It helps the vaccine look like the next important step.

The text says "the vaccine appears to have low toxicity compared to other therapies." The word "appears" hides whether this is a proven fact or just a guess. The bias helps the vaccine look safer than other treatments. It hides any proof that might still be missing.

The text says "researchers noted that patients whose cancers did not return also showed the most robust immune response." The word "noted" hides whether this is a strong finding or just an observation. The bias makes the link between the vaccine and good results seem stronger than it might be.

The text says "50 patients received standard treatment consisting of surgery followed by immunotherapy, while 107 patients also received a personalized vaccine." The group sizes are not equal, with more people getting the vaccine. The bias hides whether this difference might change the results. It makes the comparison seem fair when it might not be.

The text says "all participants had at least Stage 3 melanoma, meaning the cancer had spread to nearby lymph nodes and carried a high risk of recurrence." This makes all the patients sound very sick. The bias helps the reader think the vaccine works even for the worst cases. It hides whether the vaccine might work better or worse for less sick patients.

The text uses sources like the American Society of Clinical Oncology and the Journal of Clinical Oncology. These are trusted groups that help the story look true. But the text does not use any sources that might question the results. The bias helps the side that supports the vaccine. It hides any doubts other scientists might have.

The text says "the vaccine, developed by Moderna, uses mRNA technology." Naming Moderna helps the company look like a hero. The bias helps Moderna's image and stock value. It hides other companies that might be working on similar treatments.

The text says "if that trial yields similar findings, experts say it could represent a major shift in cancer treatment." The phrase "major shift" is a strong claim that makes the vaccine sound like it will change everything. The bias pushes the reader to believe this is a sure thing. It hides how many new treatments fail even after early good results.

The text does not talk about how much the vaccine might cost or who will be able to get it. This leaves out the side of the story about money and access. The bias helps the companies and rich countries look good. It hides people who might not be able to afford the treatment.

The text says "patients received up to nine doses spaced about three weeks apart." The word "up to" hides how many doses each person really got. The bias makes the treatment sound simple. It hides how hard it might be for patients to get so many doses.

The text says "the vaccine appears to have low toxicity compared to other therapies." The phrase "compared to other therapies" hides which therapies are being compared. The bias makes the vaccine look better without showing the full picture. It hides any therapies that might be just as safe or safer.

The text says "researchers are now compiling the results" about the phase 3 trial. This hides whether the results are ready or still far away. The bias keeps the reader excited and hopeful. It hides any delays or problems in the big trial.

The text says "nearly 70 percent of patients who received the vaccine were cancer-free." The word "nearly" could mean 69 percent or 65 percent. This soft word hides the real number. The bias makes the success sound bigger than it might be. It hides the exact truth from the reader.

The text says "cut the risk of cancer metastasizing by nearly 60 percent." The phrase "cut the risk" makes it sound like the vaccine stopped the cancer from spreading. The bias helps the reader believe the vaccine is very powerful. It hides whether other factors might have helped too.

The text says "the vaccine appears to have low toxicity." The word "appears" is soft and hides whether this is a fact or just what researchers think. The bias helps the vaccine look safe without full proof. It hides any risks that might still be unknown.

The text says "side effects reported were similar to those from mRNA Covid vaccines." This comparison to Covid vaccines might make some readers feel safe and others feel worried. The bias hides how different people might react. It uses a known vaccine to make this new one feel familiar.

The text says "patients whose cancers did not return also showed the most robust immune response after vaccination." This leads the reader to believe the strong immune response caused the cancer to stay away. The bias hides other reasons why some patients did better. It makes the vaccine seem like the only cause.

The text says "a larger phase 3 trial involving 1,000 patients across the United States, Australia, and Europe has completed treatment." The phrase "has completed treatment" hides whether the results are good or bad. The bias keeps the reader hopeful. It hides any bad news that might come from the trial.

The text says "if that trial yields similar findings, experts say it could represent a major shift." The word "could" hides whether this will really happen. The bias pushes the reader to believe the future is bright. It hides the chance that the trial might fail.

The text says "potentially opening the door to personalized mRNA vaccines for many other types of cancer." The word "potentially" hides whether this is a real plan or just a dream. The bias helps Moderna and other companies look like future leaders. It hides how many years this might take.

The text says "melanoma is the deadliest form of skin cancer." This absolute claim hides other dangerous cancers. The bias makes melanoma sound like the only big problem. It hides other skin cancers that also need attention.

The text says "in about half of patients, the disease returns within the first five years." The phrase "about half" is soft and hides the real number. The bias makes the problem sound very big. It hides any progress that has already been made.

The text says "undetectable cancer cells often remain in the body afterward." The word "often" hides how common this is. The bias makes surgery sound like it is not enough. It helps the vaccine look like a needed next step.

The text says "the vaccine appears to have low toxicity compared to other therapies." The phrase "compared to other therapies" hides which ones. The bias makes the vaccine look better without full proof. It hides any therapies that might be just as good.

The text says "researchers noted that patients whose cancers did not return also showed the most robust immune response." The word "also" hides whether the immune response caused the good results. The bias makes the link seem stronger than it might be. It hides other reasons patients stayed healthy.

The text says "50 patients received standard treatment while 107 patients also received a personalized vaccine." The groups are not the same size. The bias hides whether this matters for the results. It makes the comparison seem fair when it might not be.

The text says "all participants had at least Stage 3 melanoma." This makes the patients sound very sick. The bias helps the vaccine look strong. It hides whether it would work for less sick people too.

The text uses trusted sources like the Journal of Clinical Oncology. This helps the story look true. But no sources are used that might question the results. The bias hides any doubts other scientists might have.

The text says "the vaccine, developed by Moderna, uses mRNA technology." Naming Moderna helps the company. The bias hides other companies working on similar things. It makes Moderna look like the only leader.

The text says "if that trial yields similar findings, experts say it could represent a major shift." The phrase "major shift" is a big claim. The bias hides how many treatments fail after early good results. It makes the reader believe this one will work.

The text does not talk about cost or who can get the vaccine. This leaves out the money side. The bias helps rich people and big companies. It hides people who might not be able to afford it.

The text says "patients received up to nine doses spaced about three weeks apart." The phrase "up to" hides how many doses each person got. The bias makes the treatment sound easy. It hides how hard it might be for some patients.

The text says "the vaccine appears to have low toxicity compared to other therapies." The word "appears" hides whether this is proven. The bias helps the vaccine look safe. It hides any missing proof.

The text says "researchers are now compiling the results" about the phase 3 trial. This hides whether the results are good or bad. The bias keeps the reader hopeful. It hides any problems in the trial.

The text says "nearly 70 percent of patients who received the vaccine were cancer-free." The word "nearly" hides the real number. The bias makes the success sound bigger. It hides the exact truth.

The text says "cut the risk of cancer metastasizing by nearly 60 percent." The word "nearly" hides the real number again. The bias pushes the reader to think the vaccine is very strong. It hides the full truth.

The text says "the vaccine appears to have low toxicity." The word "appears" is soft. The bias helps the vaccine look safe without full proof. It hides any unknown risks.

The text says "side effects reported were similar to those from mRNA Covid vaccines." This comparison might make some readers feel safe. The bias hides how different people might react. It uses a known vaccine to make this one feel less scary.

The text says "patients whose cancers did not return also showed the most robust immune response after vaccination." This leads the reader to believe the vaccine caused the good results. The bias hides other reasons. It makes the vaccine seem like the only cause.

The text says "a larger phase 3 trial involving 1,000 patients across the United States, Australia, and Europe has completed treatment." The phrase "has completed treatment" hides the results. The bias keeps the reader excited. It hides any bad news.

The text says "if that trial yields similar findings, experts say it could represent a major shift." The word "could" hides whether this will happen. The bias pushes the reader to believe the future is bright. It hides the chance of failure.

The text says "potentially opening the door to personalized mRNA vaccines for many other types of cancer." The word "potentially" hides whether this is real. The bias helps companies look like future leaders. It hides how long this might take.

The text says "melanoma is the deadliest form of skin cancer." This strong claim hides other dangerous cancers. The bias makes melanoma sound like the only big problem.

The text says "in about half of patients, the disease returns within the first five years." The phrase "about half" is soft. The bias makes the problem sound very big. It hides any progress.

The text says "undetectable cancer cells often remain in the body afterward." The word "often" hides how common this is. The bias makes surgery seem not enough. It helps the vaccine look needed.

The text says "the vaccine appears to have low toxicity compared to other therapies." The phrase "compared to other therapies" hides which ones. The bias makes the vaccine look better without full proof.

The text says "researchers noted that patients whose cancers did not return also showed the most robust immune response." The word "also" hides whether this caused the good results. The bias makes the link seem stronger. It hides other reasons.

The text says "50 patients received standard treatment while 107 patients also received a personalized vaccine." The groups are not equal. The bias hides whether this matters. It makes the comparison seem fair.

The text says "all participants had at least Stage 3 melanoma." This makes the patients sound very sick. The bias helps the vaccine look strong. It hides whether it works for less sick people.

The text uses trusted sources like the Journal of Clinical Oncology. This helps the story look true. But no sources question the results. The bias hides doubts.

The text says "the vaccine, developed by Moderna, uses mRNA technology." Naming Moderna helps the company. The bias hides other companies. It makes Moderna look like the only leader.

The text says "if that trial yields similar findings, experts say it could represent a major shift." The phrase "major shift" is a big claim. The bias hides how many treatments fail. It makes the reader believe this one will work.

The text does not talk about cost or access. This leaves out the money side. The bias helps rich people and big companies. It hides people who cannot afford it.

The text says "patients received up to nine doses spaced about three weeks apart." The phrase "up to" hides how many doses each person got. The bias makes the treatment sound easy. It hides how hard it might be.

The text says "the vaccine appears to have low toxicity compared to other therapies." The word "appears" hides whether this is proven. The bias helps the vaccine look safe. It hides missing proof.

The text says "researchers are now compiling the results" about the phase 3 trial. This hides whether the results are good. The bias keeps the reader hopeful. It hides problems.

The text says "nearly 70 percent of patients who received the vaccine were cancer-free." The word "nearly" hides the real number. The bias makes the success sound bigger. It hides the exact truth.

The text says "cut the risk of cancer metastasizing by nearly 60 percent." The word "nearly" hides the real number. The bias pushes the reader to think the vaccine is very strong. It hides the full truth.

The text says "the vaccine appears to have low toxicity." The word "appears" is soft. The bias helps the vaccine look safe without full proof. It hides unknown risks.

The text says "side effects reported were similar to those from mRNA Covid vaccines." This comparison might make some readers feel safe. The bias hides how different people might react. It uses a known vaccine to make this one feel less scary.

The text says "patients whose cancers did not return also showed the most robust immune response after vaccination." This leads the reader to believe the vaccine caused the good results. The bias hides other reasons. It makes the vaccine seem like the only cause.

The text says "a larger phase 3 trial involving 1,000 patients across the United States, Australia, and Europe has completed treatment." The phrase "has completed treatment" hides the results. The bias keeps the reader excited. It hides bad news.

The text says "if that trial yields similar findings, experts say it could represent a major shift." The word "could" hides whether this will happen. The bias pushes the reader to believe the future is bright. It hides the chance of failure.

The text says "potentially opening the door to personalized mRNA vaccines for many other types of cancer." The word "potentially" hides whether this is real. The bias helps companies look like future leaders. It hides how long this might take.

The text about the Moderna melanoma vaccine carries several meaningful emotions that work together to shape how the reader feels and thinks about this new treatment. The strongest and most visible emotion is hope, which runs through nearly every part of the passage. Words like "significant promise," "major shift," and "potentially opening the door" all carry a sense of optimism about what this vaccine could mean for cancer patients. This hope is strong because it is built on real numbers and real results, not just vague promises. The purpose of this hope is to make the reader feel that something genuinely good is happening in the fight against cancer, especially for people who have been affected by melanoma or who know someone who has. When the text says nearly 70 percent of patients who got the vaccine were cancer-free compared to 49 percent who did not, that number creates a feeling of encouragement because it shows a clear difference. The hope is meant to inspire patients and families to pay attention and to feel that progress is being made against a very serious disease.

Another emotion present in the text is urgency, which appears in the way melanoma is described. The passage says melanoma is the deadliest form of skin cancer and that in about half of patients the disease comes back within five years. These words carry weight because they remind the reader that melanoma is not a small problem but a very dangerous one. The phrase "deadliest form of skin cancer" is meant to make the reader feel that this disease is serious and scary, which in turn makes the vaccine seem even more important. The urgency serves a clear purpose, which is to help the reader understand why this research matters so much. Without this sense of danger, the vaccine results would not feel as meaningful. By describing how often the cancer returns and how surgery alone is not always enough, the text builds a feeling of need that makes the reader want to know more about this new treatment.

There is also a quiet emotion of relief woven into the passage, particularly where it talks about side effects. The text says the vaccine "appears to have low toxicity compared to other therapies" and that side effects were "similar to those from mRNA Covid vaccines, including flu-like symptoms such as chills and headaches that lasted only a couple of days." The phrase "only a couple of days" is important because it makes the side effects sound small and manageable. This creates a feeling of comfort for the reader, especially for anyone who might be worried about how hard cancer treatment can be on the body. The relief is subtle but meaningful because it addresses a fear that many people have about cancer drugs, which is that the treatment might be almost as bad as the disease. By comparing the side effects to something familiar like a Covid vaccine, the text makes the treatment feel less scary and more approachable.

Pride and accomplishment are also present in the text, though they are expressed through the reporting of the research rather than through direct statements. The fact that the research was presented at the American Society of Clinical Oncology and published in the Journal of Clinical Oncology gives the findings a sense of authority and importance. These are respected organizations, and mentioning them creates a feeling of trust and credibility. The text also describes the science behind the vaccine in a way that makes it sound impressive, explaining how each vaccine is designed using genetic material from a patient's tumor and how it trains T-cells to recognize and attack cancer. This description carries a quiet sense of pride in what science and medicine can achieve. The purpose of this pride is to build confidence in the reader that this is not just a small step but a meaningful advance that has been carefully studied and verified.

Fear is another emotion that appears in the text, though it is used in a specific way. The passage mentions that undetectable cancer cells often remain in the body after surgery and that the cancer had spread to nearby lymph nodes in all participants. These details create a sense of worry about what can happen even after treatment. The fear is not overwhelming, but it is present enough to make the reader understand why a new treatment is needed. This fear serves the purpose of justifying the vaccine and making the reader feel that the research is addressing a real and serious problem. It also helps the reader appreciate the results more, because the patients in the trial were very sick and still benefited from the vaccine.

The text also carries a sense of excitement, particularly in the final paragraphs where it talks about the future. The phrase "potentially opening the door to personalized mRNA vaccines for many other types of cancer beyond melanoma" creates a feeling of possibility and anticipation. The word "potentially" is soft, but the idea behind it is big, and it makes the reader think about all the other cancers that might one day be treated this way. This excitement is meant to make the reader feel that this is not just about melanoma but about a whole new way of fighting cancer. The mention of a larger phase 3 trial with 1,000 patients across multiple countries adds to this excitement because it suggests that the research is growing and that more answers are coming soon.

The writer uses several tools to increase the emotional impact of the text. One tool is the use of specific numbers, which make the results feel real and concrete. Saying that nearly 70 percent of patients were cancer-free compared to 49 percent is more powerful than simply saying the vaccine worked better. The numbers give the reader something to hold onto and make the success feel measurable. Another tool is the comparison to familiar things, like mRNA Covid vaccines. This comparison makes the new treatment feel less strange and more understandable, which reduces fear and builds trust. The writer also uses strong phrases like "major shift in cancer treatment" and "deadliest form of skin cancer" to make the stakes feel high. These phrases are not neutral, they are chosen to make the reader feel that something important is happening. The repetition of positive results throughout the text, from the survival numbers to the low side effects to the robust immune response, reinforces the feeling that this vaccine is a genuine breakthrough.

These emotions work together to guide the reader toward a hopeful but measured reaction. The hope and excitement make the reader feel good about the progress being made, while the urgency and fear remind the reader of why this matters. The relief about side effects makes the treatment seem manageable, and the pride in the science builds trust in the results. The writer does not present the information in a cold or distant way. Instead, the language is shaped to make the reader care about the story, to feel the seriousness of melanoma, and to believe that this vaccine could be an important step forward. The emotions are carefully placed to encourage the reader to pay attention, to feel encouraged, and to see this research as something worth following as the larger trial results come in.